Navigation Links
Micromet and MedImmune to Present New Clinical Data for Anti-CD19 BiTE(R) Antibody at American Society of Hematology Annual Meeting Showing Objective Clinical Responses in Relapsed Non-Hodgkin's Lymphoma Patients
Date:11/29/2007

r cell-destroying, T- cells against tumor cells, and may represent a new therapeutic approach to cancer therapy. BiTE molecules are part of a novel class of antibody derivatives with the potential to selectively direct and activate an individual's cytotoxic T-cells, the body's most potent killer cells, to act against cancer cells. BiTE antibodies have been shown to induce an immunological synapse between a T-cell and a tumor cell in the same manner as observed during physiological T-cell attacks. These cytolytic synapses enable the delivery of cytotoxic proteins from T-cells into tumor cells, ultimately inducing a self-destruction process in the tumor cell referred to as "apoptosis," or programmed cell death. In the presence of BiTE antibodies, T-cells have been demonstrated to serially eliminate tumor cells, which explains the activity of BiTE antibodies at low concentrations and at low ratios of T-cells to target tumor cells. Through the process of killing cancer cells, T-cells proliferate, which leads to an increased number of T-cells at the site of attack.

Several antibodies in Micromet's product pipeline are BiTE antibodies and have been generated based on Micromet's proprietary BiTE product development platform. In addition to current studies of MT103, three other BiTE antibodies, targeting EpCAM (CD326), CEA and MCSP, are in pre-clinical development.

BiTE is a registered trademark of Micromet.

About MT103

MT103, which is being co-developed with MedImmune as MEDI-538, is a BiTE antibody being developed with the intent to treat certain types of B-cell lymphomas. In February 2006, the U.S. Food and Drug Administration approved an orphan drug designation for MT103 for certain indolent B-cell lymphoma, excluding chronic lymphocytic leukemia and NHL with central nervous system involvement. MT103 also received orphan drug designation from the European Agency for the Evaluation of Medicinal Products for MCL and chronic lymphocytic leukemia
'/>"/>

SOURCE Micromet, Inc
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6

Related medicine news :

1. Micromet Receives Regulatory Approval to Conduct a Phase 2 Clinical Trial Investigating MT103 (MEDI-538) in Patients with Acute Lymphoblastic Leukemia
2. Micromets BiTE(R) Antibodies Reveal Unique Mode of Action
3. MedImmune Resolves FDA Observations Regarding Manufacturing Process for FluMist(R)
4. MedImmune Licenses Reverse Genetics Technology to GlaxoSmithKline for Use in Influenza Vaccine Development and Production
5. Medimmune announces phase 2 safety data for anti-RSV antibody and national RSV surveillance results
6. MedImmune to present RSV surveillance and cost-effectiveness data at American Academy of Pediatrics
7. MedImmune presents new pharmaco-economic data at AAP regarding infants at high risk for RSV
8. AtriCure to Present at Thomas Weisel Partners 2007 Healthcare Conference
9. Matrixx Initiatives, Inc. to Present at the Roth Capital Partners 2007 New York Conference
10. BD to Present at the Bear Stearns 20th Annual Healthcare Conference
11. ATS Medical to Present at the 2007 Thomas Weisel Partners Healthcare Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/25/2014)... 2014 Reproductive Science Center (RSC) of ... Kerri Luzzo, Lead Physician at RSC Rhode Island, received ... accomplishments in fertility care and community outreach issued by ... Annual PBN Awards ceremony held July 24th at Salve ... most highly regarded, emerging leaders in their field were ...
(Date:7/25/2014)... 25, 2014 (HealthDay News) -- The human brain can ... dehydration, a new study finds. Although dehydration ... England have found that the brain compensates by increasing ... "This research has helped us understand a lot ... exercise in extreme conditions," study first author Steven Trangmar, ...
(Date:7/25/2014)... ON (PRWEB) July 25, 2014 A new ... Hospital revealed that 39 percent of all children in the ... dentist. , The survey looked at 2,505 children during the years ... around four years of age. The final result was that ... dental care. Many of these children were from lower-income families and ...
(Date:7/25/2014)... On July 22, 2014, CEDR ... the nation’s number one provider of legally-compliant, individually ... partnership with TransAct Merchant Solutions’ National Association Program ... Chase Paymentech Solutions, LLC, which provides sales and ... are members of TransAct’s National Association Program (NAP) ...
(Date:7/25/2014)... Philadelphia, PA (PRWEB) July 25, 2014 ... that Valerie D. Weber, MD, MS, FACP, has been appointed ... , Weber will join Drexel from The Commonwealth Medical College, ... Sciences, associate dean for clinical affairs, and professor of medicine. ... of The Commonwealth Medical College, Weber had a major role ...
Breaking Medicine News(10 mins):Health News:Dr. Kerri Luzzo of the Reproductive Science Center of Providence Receives “40 Under Forty Award" for Outstanding Professional Accomplishments and Community Outreach 2Health News:Human Brain Has Coping Mechanism for Dehydration 2Health News:North York Dental Provides Services to Toronto Children in Light of Growing Demand 2Health News:North York Dental Provides Services to Toronto Children in Light of Growing Demand 3Health News:Nuanced Media Client, CEDR HR Solutions, Partners with TransAct to Serve Medical, Dental, and Eye Care Professionals 2Health News:Valerie D. Weber, MD, Appointed Vice Dean for Education at Drexel University College of Medicine 2Health News:Valerie D. Weber, MD, Appointed Vice Dean for Education at Drexel University College of Medicine 3
... withdrawal of seven lines of their products Cadbury Schweppes ... more products because of salmonella contamination. ,Cadbury, ... withdraw seven lines of chocolates last month after admitting ... ,Reports of further testing and possible withdrawal of ...
... patisseries, Choco Fudge has been adjudged the best cookie amidst ... panel consisted of eminent writers and fashion designers from Kolkata, ... of place at all ITC hotels across the country as ... contest in Kolkata, ITC Hotels aims to give a boost ...
... to a new study, contrast-enhanced sonography compared with sonography ... the assessment of blunt abdominal trauma.// ,Massimo Valentino, ... of our study was to prospectively compare the diagnostic ... detection of solid organ injuries in blunt abdominal trauma ...
... about subject as sex is, perhaps vying with each other ... well known - responsible //for many diseases, failed pregnancy, miscarriage, ... a host of problems, like ADHD in the child and ... woman’s memory and hormonal cycles. ,Women seem to be ...
... H5N1 strain of bird flu has been detected in remote ... country to be hit by bird flu. ,Although ... cases have gone unnoticed. Currently 14 of Nigeria's 36 states ... "We have identified it in three places in Taraba, one ...
... says ‘significant fluctuations in the first hour blood pressure ... ,According to this study patient mortality increases ... rooted to an impaired autoregulation of blood pressure. ... ischemic stroke symptoms of less than 24 hours. Blood ...
Cached Medicine News:Health News:New Tool Found to be Effective in Assessing Blunt Abdominal Trauma 2Health News:Fluctuating BP and Stroke Lowered Patient Survival Rate 2
(Date:7/24/2014)... , Germany , and ... , Exclusive global license from ... SF3B1 mutations, including next-generation sequencing (NGS) gene panels, for ... be targeted by new test, indicate favorable prognosis for ... QIAGEN sees potential for developing companion diagnostics ...
(Date:7/24/2014)... July 24, 2014  Mettler-Toledo International Inc. (NYSE: ... 2014.  Provided below are the highlights: , ... quarter compared with the prior year. Reported sales increased ... , Net earnings per diluted share as reported (EPS) ... of 2013. Adjusted EPS was $2.57, an increase of ...
(Date:7/24/2014)... , July 24, 2014 Omnicell, ... provider of medication and supply management solutions and ... call Thursday, July 31, to discuss the Company,s ... Omnicell Second Quarter 2014 earnings conference call and ... PTWho:  , Randall Lipps, chairman, president and chief ...
Breaking Medicine Technology:QIAGEN Adds Promising Genomic Biomarkers for Assessing Prognosis in Treatment of Blood Cancers to Personalized Healthcare Pipeline 2QIAGEN Adds Promising Genomic Biomarkers for Assessing Prognosis in Treatment of Blood Cancers to Personalized Healthcare Pipeline 3QIAGEN Adds Promising Genomic Biomarkers for Assessing Prognosis in Treatment of Blood Cancers to Personalized Healthcare Pipeline 4QIAGEN Adds Promising Genomic Biomarkers for Assessing Prognosis in Treatment of Blood Cancers to Personalized Healthcare Pipeline 5Mettler-Toledo International Inc. Reports Second Quarter 2014 Results 2Mettler-Toledo International Inc. Reports Second Quarter 2014 Results 3Mettler-Toledo International Inc. Reports Second Quarter 2014 Results 4Mettler-Toledo International Inc. Reports Second Quarter 2014 Results 5Mettler-Toledo International Inc. Reports Second Quarter 2014 Results 6Mettler-Toledo International Inc. Reports Second Quarter 2014 Results 7Mettler-Toledo International Inc. Reports Second Quarter 2014 Results 8Mettler-Toledo International Inc. Reports Second Quarter 2014 Results 9Mettler-Toledo International Inc. Reports Second Quarter 2014 Results 10Mettler-Toledo International Inc. Reports Second Quarter 2014 Results 11Mettler-Toledo International Inc. Reports Second Quarter 2014 Results 12Mettler-Toledo International Inc. Reports Second Quarter 2014 Results 13Mettler-Toledo International Inc. Reports Second Quarter 2014 Results 14Omnicell to Release Second Quarter 2014 Earnings Results on July 31 2
... 2011 Masimo (NASDAQ: ... of Health & Human Services (HHS) has added Critical ... as a national newborn screening standard.  In addition, the ... detection, published online in the Lancet (appearing ...
... or the "Company") (NASDAQ: UNIS ; ASX: UNS) ... to purchase an additional U.S. $500,000 in shares of the ... 30th. These purchases of Unilife shares will be part of ... $1.0 million in shares by September 30th. This ...
Cached Medicine Technology:U.S. Health & Human Services Makes Critical Congenital Heart Defect Screening Using Motion-Tolerant Pulse Oximetry a Nationwide Newborn Screening Standard 2U.S. Health & Human Services Makes Critical Congenital Heart Defect Screening Using Motion-Tolerant Pulse Oximetry a Nationwide Newborn Screening Standard 3U.S. Health & Human Services Makes Critical Congenital Heart Defect Screening Using Motion-Tolerant Pulse Oximetry a Nationwide Newborn Screening Standard 4U.S. Health & Human Services Makes Critical Congenital Heart Defect Screening Using Motion-Tolerant Pulse Oximetry a Nationwide Newborn Screening Standard 5U.S. Health & Human Services Makes Critical Congenital Heart Defect Screening Using Motion-Tolerant Pulse Oximetry a Nationwide Newborn Screening Standard 6U.S. Health & Human Services Makes Critical Congenital Heart Defect Screening Using Motion-Tolerant Pulse Oximetry a Nationwide Newborn Screening Standard 7U.S. Health & Human Services Makes Critical Congenital Heart Defect Screening Using Motion-Tolerant Pulse Oximetry a Nationwide Newborn Screening Standard 8U.S. Health & Human Services Makes Critical Congenital Heart Defect Screening Using Motion-Tolerant Pulse Oximetry a Nationwide Newborn Screening Standard 9U.S. Health & Human Services Makes Critical Congenital Heart Defect Screening Using Motion-Tolerant Pulse Oximetry a Nationwide Newborn Screening Standard 10Unilife CEO to Purchase an Additional U.S. $500,000 in Company Shares by September 30, 2011 2Unilife CEO to Purchase an Additional U.S. $500,000 in Company Shares by September 30, 2011 3
Half Trial Frames with precision engineering and lightweight material....
The award-winning new Universal Trial Frame (UB4), the ergonomic refraction design from Oculus that's easier to use, easier to wear....
Half Eye Trial Frame - Child...
... Universal Trial Frame comes at a very attractive price. ,The ... Temple length 4 1/8" to 5 1/2" (98 to ... to 30, PD adjustable 24 to 40mm on each ... on each lens: left - 120 to 0 to 135 ...
Medicine Products: